Amniotic fluid and placental membranes

Unexpected sources of highly multipotent cells

Sean V. Murphy, Anthony Atala

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In recent years, gestational tissue such as the placenta, placental membranes, umbilical cord, and amniotic fluid have been recognized as an untapped resource for the field of regenerative medicine. These tissues have been shown to be a rich source of multipotent and pluripotent stem cells with potent immunosuppressive properties that make these cells an exciting new tool for the treatment of disease [1–5]. Gestational tissue offers a considerable advantage as a stem-cell source over “traditional sources” such as bone marrow or embryo-derived cells. Such tissue is often discarded following birth so does not require an invasive biopsy or the destruction of a human embryo. This means that there are no ethical and legal considerations associated with their collection and use. Early investigation into gestational tissue-derived stem cells identified multipotent hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), stem cells from umbilical-cord blood [6]. HSCs have been shown to have important clinical applications for the treatment of blood-related disorders such as sickle cell disease, thalassemia, and leukemia. MSCs are currently being used in clinical trials for the treatment of various diseases such as graft vs. host disease and intervertebral disc disease. Recently, researchers have isolated and characterized highly multipotent cells from the amniotic fluid and placental membranes [1,2]. The highly multipotent and anti-inflammatory properties of these amniotic fluid-derived stem cells (AFSCs) suggest potential clinical applications of these cells to treat diseases including bone defects, lung disease, neurological disorders, kidney disease, and heart disease [7–11]. This chapter will focus on AFSCs isolated from the amniotic fluid and placental membranes, discussing their properties and potential clinical applications.

Original languageEnglish (US)
Title of host publicationStem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential
PublisherCambridge University Press
Pages102-114
Number of pages13
ISBN (Print)9781139540742, 9781107034471
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Amniotic Fluid
Stem Cells
Membranes
Multipotent Stem Cells
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Embryonic Structures
Pluripotent Stem Cells
Regenerative Medicine
Thalassemia
Umbilical Cord
Bone Diseases
Kidney Diseases
Sickle Cell Anemia
Immunosuppressive Agents
Nervous System Diseases
Fetal Blood
Placenta
Lung Diseases
Heart Diseases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Murphy, S. V., & Atala, A. (2011). Amniotic fluid and placental membranes: Unexpected sources of highly multipotent cells. In Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential (pp. 102-114). Cambridge University Press. https://doi.org/10.1017/CBO9781139540742.011

Amniotic fluid and placental membranes : Unexpected sources of highly multipotent cells. / Murphy, Sean V.; Atala, Anthony.

Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential. Cambridge University Press, 2011. p. 102-114.

Research output: Chapter in Book/Report/Conference proceedingChapter

Murphy, SV & Atala, A 2011, Amniotic fluid and placental membranes: Unexpected sources of highly multipotent cells. in Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential. Cambridge University Press, pp. 102-114. https://doi.org/10.1017/CBO9781139540742.011
Murphy SV, Atala A. Amniotic fluid and placental membranes: Unexpected sources of highly multipotent cells. In Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential. Cambridge University Press. 2011. p. 102-114 https://doi.org/10.1017/CBO9781139540742.011
Murphy, Sean V. ; Atala, Anthony. / Amniotic fluid and placental membranes : Unexpected sources of highly multipotent cells. Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential. Cambridge University Press, 2011. pp. 102-114
@inbook{55023fefe5254cfa9670dca3eb2dc352,
title = "Amniotic fluid and placental membranes: Unexpected sources of highly multipotent cells",
abstract = "In recent years, gestational tissue such as the placenta, placental membranes, umbilical cord, and amniotic fluid have been recognized as an untapped resource for the field of regenerative medicine. These tissues have been shown to be a rich source of multipotent and pluripotent stem cells with potent immunosuppressive properties that make these cells an exciting new tool for the treatment of disease [1–5]. Gestational tissue offers a considerable advantage as a stem-cell source over “traditional sources” such as bone marrow or embryo-derived cells. Such tissue is often discarded following birth so does not require an invasive biopsy or the destruction of a human embryo. This means that there are no ethical and legal considerations associated with their collection and use. Early investigation into gestational tissue-derived stem cells identified multipotent hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), stem cells from umbilical-cord blood [6]. HSCs have been shown to have important clinical applications for the treatment of blood-related disorders such as sickle cell disease, thalassemia, and leukemia. MSCs are currently being used in clinical trials for the treatment of various diseases such as graft vs. host disease and intervertebral disc disease. Recently, researchers have isolated and characterized highly multipotent cells from the amniotic fluid and placental membranes [1,2]. The highly multipotent and anti-inflammatory properties of these amniotic fluid-derived stem cells (AFSCs) suggest potential clinical applications of these cells to treat diseases including bone defects, lung disease, neurological disorders, kidney disease, and heart disease [7–11]. This chapter will focus on AFSCs isolated from the amniotic fluid and placental membranes, discussing their properties and potential clinical applications.",
author = "Murphy, {Sean V.} and Anthony Atala",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9781139540742.011",
language = "English (US)",
isbn = "9781139540742",
pages = "102--114",
booktitle = "Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Amniotic fluid and placental membranes

T2 - Unexpected sources of highly multipotent cells

AU - Murphy, Sean V.

AU - Atala, Anthony

PY - 2011/1/1

Y1 - 2011/1/1

N2 - In recent years, gestational tissue such as the placenta, placental membranes, umbilical cord, and amniotic fluid have been recognized as an untapped resource for the field of regenerative medicine. These tissues have been shown to be a rich source of multipotent and pluripotent stem cells with potent immunosuppressive properties that make these cells an exciting new tool for the treatment of disease [1–5]. Gestational tissue offers a considerable advantage as a stem-cell source over “traditional sources” such as bone marrow or embryo-derived cells. Such tissue is often discarded following birth so does not require an invasive biopsy or the destruction of a human embryo. This means that there are no ethical and legal considerations associated with their collection and use. Early investigation into gestational tissue-derived stem cells identified multipotent hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), stem cells from umbilical-cord blood [6]. HSCs have been shown to have important clinical applications for the treatment of blood-related disorders such as sickle cell disease, thalassemia, and leukemia. MSCs are currently being used in clinical trials for the treatment of various diseases such as graft vs. host disease and intervertebral disc disease. Recently, researchers have isolated and characterized highly multipotent cells from the amniotic fluid and placental membranes [1,2]. The highly multipotent and anti-inflammatory properties of these amniotic fluid-derived stem cells (AFSCs) suggest potential clinical applications of these cells to treat diseases including bone defects, lung disease, neurological disorders, kidney disease, and heart disease [7–11]. This chapter will focus on AFSCs isolated from the amniotic fluid and placental membranes, discussing their properties and potential clinical applications.

AB - In recent years, gestational tissue such as the placenta, placental membranes, umbilical cord, and amniotic fluid have been recognized as an untapped resource for the field of regenerative medicine. These tissues have been shown to be a rich source of multipotent and pluripotent stem cells with potent immunosuppressive properties that make these cells an exciting new tool for the treatment of disease [1–5]. Gestational tissue offers a considerable advantage as a stem-cell source over “traditional sources” such as bone marrow or embryo-derived cells. Such tissue is often discarded following birth so does not require an invasive biopsy or the destruction of a human embryo. This means that there are no ethical and legal considerations associated with their collection and use. Early investigation into gestational tissue-derived stem cells identified multipotent hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), stem cells from umbilical-cord blood [6]. HSCs have been shown to have important clinical applications for the treatment of blood-related disorders such as sickle cell disease, thalassemia, and leukemia. MSCs are currently being used in clinical trials for the treatment of various diseases such as graft vs. host disease and intervertebral disc disease. Recently, researchers have isolated and characterized highly multipotent cells from the amniotic fluid and placental membranes [1,2]. The highly multipotent and anti-inflammatory properties of these amniotic fluid-derived stem cells (AFSCs) suggest potential clinical applications of these cells to treat diseases including bone defects, lung disease, neurological disorders, kidney disease, and heart disease [7–11]. This chapter will focus on AFSCs isolated from the amniotic fluid and placental membranes, discussing their properties and potential clinical applications.

UR - http://www.scopus.com/inward/record.url?scp=84925645506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925645506&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139540742.011

DO - 10.1017/CBO9781139540742.011

M3 - Chapter

SN - 9781139540742

SN - 9781107034471

SP - 102

EP - 114

BT - Stem Cells in Reproductive Medicine: Basic Science and Therapeutic Potential

PB - Cambridge University Press

ER -